[Neutrophil-rich, anaplastic CD30+ T cell lymphoma in conjunction with lymphomatoid papulosis].
The 2005 EORTC/WHO classification includes three CD30+ lymphoproliferative disorders: 1) primary cutaneous anaplastic large cell lymphoma, 2) lymphomatoid papulosis and 3) borderline cases. These entities may present with many different clinical appearances. Therefore, a precise differentiation among them often is impossible. We present a 40-year-old female who initially presented with a neutrophil-rich, anaplastic CD30+ T cell lymphoma followed by lymphomatoid papulosis.
Slotosch
C M
CM
Klinik für Dermatologie und Allergologie, Universitätsklinikum Giessen und Marburg GmbH, Standort Marburg, Deutschhausstr. 9, 35033 , Marburg, Germany.
Hörster
S
S
Hertl
M
M
Schultz
E
E
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004804:Eosinophils / Q000473:pathology; D005153:Facial Neoplasms / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000473:pathology; D054446:Lymphoma, Primary Cutaneous Anaplastic Large Cell / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D017731:Lymphomatoid Papulosis / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008727:Methotrexate / Q000627:therapeutic use; D009378:Neoplasms, Multiple Primary / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D009504:Neutrophils / Q000473:pathology*; D011701:PUVA Therapy; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology
D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate